StephanieBoisclairMD

Hematologic Oncology

Physician

Dr. Boisclair is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

1 citations
CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis.
A Samer Al-Homsi, Todd E DeFor, Kelli Cole, Frank Cirrone, Stephanie King
Transplantation and Cellular Therapy. 2024-11-01
Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML.
Stephanie Boisclair, Edward Zhou, Phyu Naing, Richa Thakur, Erin Jou
Leukemia Research. 2024-08-01
1 citations
Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Farhana Begum, Nida Khan, Stephanie Boisclair, Deepa A Malieckal, David Chitty
American Journal of Therapeutics. 2023-05-01

Abstracts/Posters

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019